论文部分内容阅读
目的 构建用于子宫颈癌治疗的HPV16型E6和E7重组痘苗病毒实验性疫苗株 ,并对其抗肿瘤免疫效果进行初步评价。方法 以痘苗病毒为载体、利用同源重组技术构建共表达HPV16E6和E7基因的重组痘苗病毒。该病毒免疫C57BL 6小鼠后 ,检测其免疫原性和抗移植瘤生长情况。结果 PCR结果显示 ,重组病毒VmE6E7的TK基因内插入了分别由痘苗病毒早晚期启动子H6和7.5K表达的ME6和ME7 1基因。动物实验结果表明 ,rVmE6E7在C57BL 6小鼠体内可诱发E6和E7特异性抗体产生 ,被免疫小鼠能够抵抗HPV16E6E7转化的同系肿瘤细胞的攻击。结论 获得 1株用于宫颈癌治疗的HPV16型实验疫苗株 ,为进一步研制人用HPV16型疫苗株奠定了基础。
Objective To construct an experimental vaccine strain of HPV16 E6 and E7 recombinant vaccinia virus for cervical cancer treatment and evaluate its anti-tumor immunity effect. Methods Vaccinia virus was used as a vector to construct recombinant vaccinia virus coexpressing HPV16 E6 and E7 genes by homologous recombination technique. The virus was immunized C57BL 6 mice, tested for their immunogenicity and anti-tumor growth. Results The PCR results showed that the genes of ME6 and ME7 1 expressed by vaccinia virus early and late promoters H6 and 7.5K, respectively, were inserted into the TK gene of VmE6E7. Animal experiments show that rVmE6E7 can induce E6 and E7 specific antibody production in C57BL 6 mice, and the immunized mice can resist the attack of HPV16E6E7 transformed homologous tumor cells. Conclusion An HPV16 experimental vaccine strain for cervical cancer treatment was obtained, which laid the foundation for the further development of human HPV16 vaccine strain.